Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
about
Identification of an antiapoptotic protein complex at death receptorsHGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoNewcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell deathOnto better TRAILs for cancer treatmentPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Novel agents for advanced pancreatic cancerPrinciples of antibody-mediated TNF receptor activationHarnessing the apoptotic programs in cancer stem-like cellsStructural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5Following a TRAIL: update on a ligand and its five receptorsTrailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsThe novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5Anti-DR5 mAb ameliorate adjuvant arthritis rats through inducing synovial cells apoptosisFlavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cellsEarly therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopySynthetic antibodies as therapeutics.Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism.Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells.Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death.PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumorsModulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosisDCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapyPredominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.T cells require TRAIL for optimal graft-versus-tumor activity.Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4+ T cells and apoptosis.Multi-targeted therapy of cancer by niclosamide: A new application for an old drug.Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells.TRAIL in cancer therapy: present and future challenges.TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cellsStructural basis of LaDR5, a novel agonistic anti-death receptor 5 (DR5) monoclonal antibody, to inhibit DR5/TRAIL complex formationRequirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.TRAIL/Apo-2L: mechanisms and clinical applications in cancer.
P2860
Q24321594-42D77289-A1A6-4553-AB9E-5C67B344CD6DQ24650617-A130F250-8D23-4982-965A-34FED5BF12E0Q24674186-DE648308-B8CF-4991-9034-16C66889A9C8Q26768160-32C39239-5F9C-4649-B538-0AF5BDF0A096Q26771601-D7F8DE1F-2015-4869-B19D-747E7AA59459Q26787087-83F1534B-3737-4BA5-9683-DE7BF347E7DDQ26796270-673E6EA9-2632-49E7-9F7E-AD3479926671Q26801037-DA60296B-618E-455F-9A90-CDC26937A780Q27649718-6DD4B522-9342-4D6A-BC1F-06B55B1C362FQ28292767-0072DCF0-98BB-4723-A1FA-E9336625E86AQ28391040-765DB631-D312-4014-AE9E-900AC1B59E89Q28392681-11D42748-7BD7-4B7A-9574-40AB871BAC3CQ28581237-570016CD-469C-4E25-A66F-DD12A5701F3FQ28817517-1B6642B3-1FA4-4F53-A4D6-BC7910191584Q30682911-563A9F68-817F-42DD-91B1-AE07158BA0CFQ33265617-EED4D522-1802-4AED-8D1C-947BE8E9ECD8Q33421148-8003B92D-765F-44F0-9A6B-4D4A6AA01ECCQ33523440-7AAE1EEF-43FA-4554-8FB6-CB178B64AC2BQ33618126-30D9B0AF-F181-4EED-AF88-2772BE4B75EAQ33723716-E052023D-6D5F-4C76-866A-291262B4A4D3Q33726537-FA32EBED-BA81-40A4-A8BC-3B06B5A97374Q33731141-36A03FE7-DFBD-4F68-A338-58CA039D6CAFQ33753135-8B552198-588B-4240-8535-7F4D6D7D0675Q33805582-B7572A12-8A13-431F-8A56-B21170010A83Q33862991-F06A5F66-CFB9-4C7E-B435-89BD66DDAC16Q33906524-A7680EAF-205B-4A50-A60C-2F4A02A87B8CQ33989940-C3079F55-73B7-4398-8F30-1783FA28347BQ33991741-E9CC06C3-4D3F-4B5D-AF10-A20ACCA781A2Q34066039-2EDB3198-57B7-4AAC-89E8-EC4700F210A8Q34132999-BA871B96-E97F-467C-B52A-EC0A722DDA3BQ34158517-DFC4F1D8-2555-4A8C-8DB3-7B39F7791B00Q34193462-E899B7CE-97DF-427F-AECF-4C652D378EC8Q34199032-EB1DBAAE-E271-476F-AD85-38BEE1FCE936Q34219368-A29D2F53-1EC3-42F0-B3C1-FCC4C49A15D5Q34272896-E4CC3199-226A-4AEF-9674-D283A7676B84Q34291312-9616A1AF-DEC8-450C-A536-D8754CF9CAE7Q34324431-A784F642-8139-4BE1-A385-FADC6633DFF9Q34334395-70E5977C-FFA8-4CE8-8D65-F32AD2EB20A6Q34390964-781BE7C6-F002-4009-AE1E-E430E29C2D46Q34482821-803D01CB-4B36-4615-AABE-6517190F9ED8
P2860
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Tumoricidal activity of a nove ...... thout hepatocyte cytotoxicity.
@en
type
label
Tumoricidal activity of a nove ...... thout hepatocyte cytotoxicity.
@en
prefLabel
Tumoricidal activity of a nove ...... thout hepatocyte cytotoxicity.
@en
P2093
P356
P1433
P1476
Tumoricidal activity of a nove ...... ithout hepatocyte cytotoxicity
@en
P2093
Ichikawa K
Koopman WJ
P2888
P304
P356
10.1038/91000
P407
P577
2001-08-01T00:00:00Z